
SeraCare Life Sciences Acquires KPL
The acquisition expands SeraCare's portfolio of products designed to help diagnostic researchers develop in vitro diagnostic assays.
By acquiring KPL, SeraCare has built upon its position as a life science consumables provider for diagnostic research. KPL’s portfolio of products includes high quality immunochemicals for in vitro diagnostics, including primary and secondary antibodies as well as reagents and kits targeting ELISA, western blotting, immunohistology, protein labeling, nucleic acid labeling, sample preparation, protein purification, and recombinant protein detection and analysis. These products will assist SeraCare’s expansion from its core strength of providing biological products and control materials for infectious disease, women’s health, and genetic testing into oncology, autoimmune, allergy, and companion diagnostics.
Source:
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.





